Wire open Last filed GLP 1 cold medicine advice flags NSAIDs and pill timing in flu season RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news, filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineSAFAnalysis

GLP 1 cold medicine advice flags NSAIDs and pill timing in flu season

A pharmacist and three physicians told Yahoo Health that people on GLP 1 drugs should rethink NSAIDs, sedating antihistamines and combination cold products. The FDA's Wegovy label ties most kidney injury reports to dehydration.

NEW YORK

600+Medicines that contain acetaminophen, per the FDA, a double dosing risk in combination cold products
  1. What's newA pharmacist and three physicians told Yahoo Health that people on GLP 1 drugs should rethink NSAIDs, older sedating antihistamines and multi-symptom cold products, and plan pill timing during illness.
  2. Why it mattersStomach side effects of GLP 1 drugs can overlap with those of cold remedies, and the FDA's Wegovy label links most reported acute kidney injury cases to dehydration from vomiting or diarrhea.
  3. What's nextThe advice is expert opinion, not a trial result. Patients are urged to ask for a sick day plan, and the orforglipron and Paxlovid warning has yet to be checked against the label.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. IND · 31 Oct 2026PolyPeptide shareholders approved all board proposals on 26 October 2026, choosing five directors with John Chongbo Rim as chair and voting to remove transfer restrictions and voting limits from the articles.
  2. SAF · 30 Oct 2026Physician Joseph Varon of the Independent Medical Alliance told The National News Desk that some of his patients have diarrhea after meals two or three years after stopping GLP 1 drugs.
  3. IND · 30 Oct 2026Eli Lilly reported third quarter revenue of $24.4 billion, up 39%, with Mounjaro sales up 65% and Zepbound sales up 49%. It raised its 2026 revenue forecast to $91 billion to $92 billion.
  4. IND · 30 Oct 2026Lilly reported third quarter revenue of $24.4 billion, up 39%, as volume rose 53% and realized prices fell 15%. It raised its 2026 revenue forecast to $91 billion to $92 billion.
  5. TRL · 30 Oct 2026Novo Nordisk said it will present 26 obesity abstracts at ObesityWeek 2026 in Washington from November 14 to 17, including REDEFINE 9 low dose CagriSema results, REDEFINE 1 analyses, STEP Young data in children and Wegovy real world studies.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty-liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Head to head, tirzepatide beats semaglutide on weight loss 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 1.7 pointsPlacebo adjusted HbA1c drop at 12 weeks in the lowest and highest dose groups, per Ascletis TRL · 29 OCT · ASC30 diabetes trial lowers HbA1c against placebo in 12 week Phase 2 study

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Copies, risks and rules

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Oct 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Oct 2026

  • 22 DECThe first GLP-1 pill for weight management gets the green light
  • 07 AUGThe weight-loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Oct 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators9
TRLTrials20
INDIndustry11
SAFSafety17
EXPExplainers2

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator12
  • Journal9
  • Company release17
  • Conference6
  • Our newsroom15